华熙生物涨2.03%，成交额7676.89万元，主力资金净流入259.05万元

Core Viewpoint - Huaxi Biological's stock price has shown a slight decline this year, with recent trading indicating a downward trend, while the company continues to maintain a diverse business model in the biotechnology sector [2][3]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and specializes in microbial fermentation and cross-linking technology platforms [2]. - The company has developed a full industry chain business system that includes raw materials, medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing enterprises, medical institutions, and end users [2]. Financial Performance - For the period from January to September 2025, Huaxi Biological reported operating revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2]. - Since its A-share listing, Huaxi Biological has distributed a total of 1.138 billion yuan in dividends, with 528 million yuan distributed over the past three years [3]. Stock Performance - As of November 10, Huaxi Biological's stock price was 50.79 yuan per share, with a market capitalization of 24.464 billion yuan. The stock has decreased by 0.27% this year, with a 4.39% drop over the last five trading days [1][2]. - The company experienced a net inflow of main funds amounting to 2.5905 million yuan, with large orders accounting for 24.19% of total purchases [1]. Shareholder Information - As of October 31, the number of Huaxi Biological's shareholders was 30,600, an increase of 0.86% from the previous period. The average circulating shares per person decreased by 0.85% to 15,749 shares [2]. - The top ten circulating shareholders include several ETFs, with notable reductions in holdings for major funds such as E Fund and Huaxia [3].